

SAFETY DATA SHEET

LUCENTIS(R) Vials (0.3 mg/0.05 ml)

Version
0.0

Revision Date:
02-13-2020

Date of last issue: 01-30-2020
Date of first issue: 06-10-2017

SECTION 1. IDENTIFICATION

Product name : LUCENTIS(R) Vials (0.3 mg/0.05 ml)

Product code : 00010138290

Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.

Address : DNA Way 1
94080 South San Francisco
CA
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

Emergency telephone number : US Chemtrec phone (800)-424-9300

Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance

Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Ranibizumab	347396-82-1	0.6
Trehalose (D+)-, 2H ₂ O	6138-23-4	10.0
L-Histidine monohydrochloride monohydrate	5934-29-2	0.17
L-Histidine	71-00-1	0.03
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.01
Water	7732-18-5	> 89.0

LUCENTIS(R) Vials (0.3 mg/0.05 ml)

Version
0.0

Revision Date:
02-13-2020

Date of last issue: 01-30-2020
Date of first issue: 06-10-2017

SECTION 4. FIRST AID MEASURES

- General advice : Do not leave the victim unattended.
- If inhaled : Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.
- In case of skin contact : If on skin, rinse well with water.
- In case of eye contact : Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.
- If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.
- Most important symptoms and effects, both acute and delayed : None known.
- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Specific hazards during fire fighting : No information available.
- Hazardous combustion products : No hazardous combustion products are known
- Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Refer to protective measures listed in sections 7 and 8.
- Environmental precautions : Local authorities should be advised if significant spillages

LUCENTIS(R) Vials (0.3 mg/0.05 ml)

Version
0.0

Revision Date:
02-13-2020

Date of last issue: 01-30-2020
Date of first issue: 06-10-2017

cannot be contained.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).
Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions : See label, package insert or internal guidelines

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protected from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Stainless steel, glass, Vials, Prefilled syringes

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ranibizumab	347396-82-1	IOEL	0.2 mg/m3	Roche Industrial Hygiene Committee (RIHC)

Engineering measures : No data available

Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally required.

Hand protection

Material : Protective gloves

LUCENTIS(R) Vials (0.3 mg/0.05 ml)Version
0.0Revision Date:
02-13-2020Date of last issue: 01-30-2020
Date of first issue: 06-10-2017

Remarks : Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution, Sterile liquid

Color : colorless, light yellow

Odor : No data available

Odor Threshold : No data available

pH : 5.5

Melting point/range : No data available

Boiling point/boiling range : No data available

Flash point : does not flash

Evaporation rate : No data available

Flammability (solid, gas) : Does not sustain combustion.

Flammability (liquids) : Does not sustain combustion.

Self-ignition : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Solubility(ies)
Water solubility : completely miscible

Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

LUCENTIS(R) Vials (0.3 mg/0.05 ml)Version
0.0Revision Date:
02-13-2020Date of last issue: 01-30-2020
Date of first issue: 06-10-2017

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

 Viscosity, dynamic : No data available

 Viscosity, kinematic : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Stable under recommended storage conditions.
No hazards to be specially mentioned.

Incompatible materials : No data available

Hazardous decomposition products : No data available

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity**

Not classified based on available information.

Components:**Ranibizumab:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Trehalose (D+)-, 2H₂O:Acute oral toxicity : Acute toxicity estimate: > 5,001 mg/kg
Method: Expert judgment

TDLo (Rat): 16,000 mg/kg

Acute inhalation toxicity : Acute toxicity estimate: > 30 mg/l
Test atmosphere: dust/mist
Method: Expert judgmentAcute dermal toxicity : Acute toxicity estimate: > 5,001 mg/kg
Method: Expert judgment**L-Histidine monohydrochloride monohydrate:**Acute toxicity (other routes of administration) : TDLo (Rat): 1,500 mg/kg
Application Route: i.p.**L-Histidine:**

Acute oral toxicity : LD50 Oral (Rat): > 15,000 mg/kg

LUCENTIS(R) Vials (0.3 mg/0.05 ml)Version
0.0Revision Date:
02-13-2020Date of last issue: 01-30-2020
Date of first issue: 06-10-2017

LD50 Oral (Mouse): > 15,000 mg/kg

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:

Acute oral toxicity : LD50 Oral (Rat): 38,900 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**Genotoxicity in vitro : Test Type: Ames test
Result: negative

Germ cell mutagenicity - Assessment : Tests on bacterial or mammalian cell cultures did not show mutagenic effects.

Carcinogenicity

Not classified based on available information.

Components:**L-Histidine monohydrochloride monohydrate:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

L-Histidine:

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

LUCENTIS(R) Vials (0.3 mg/0.05 ml)

Version
0.0

Revision Date:
02-13-2020

Date of last issue: 01-30-2020
Date of first issue: 06-10-2017

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Ranibizumab:

Effects on fetal development : Result: Based on its mechanism of action, effects on embryofetal development can be assumed

STOT-single exposure

Not classified based on available information.

Components:

Trehalose (D+)-, 2H₂O:

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

L-Histidine monohydrochloride monohydrate:

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure

Not classified based on available information.

Components:

Trehalose (D+)-, 2H₂O:

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

L-Histidine monohydrochloride monohydrate:

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Aspiration toxicity

Not classified based on available information.

Components:

Trehalose (D+)-, 2H₂O:

No data available

L-Histidine monohydrochloride monohydrate:

No data available

LUCENTIS(R) Vials (0.3 mg/0.05 ml)

 Version
 0.0

 Revision Date:
 02-13-2020

 Date of last issue: 01-30-2020
 Date of first issue: 06-10-2017

Further information
Components:
Ranibizumab:

Remarks : anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

SECTION 12. ECOLOGICAL INFORMATION
Components:
Trehalose (D+)-, 2H₂O:

 Toxicity to fish : LC50: > 100 mg/l
 Exposure time: 96 h

Toxicity to fish (Chronic toxicity) : > 1 mg/l

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

L-Histidine monohydrochloride monohydrate:
Ecotoxicology Assessment

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:

 Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 216 mg/l
 Exposure time: 96 h

 LC50 (Brachydanio rerio (zebrafish)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203
 GLP: yes

 Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 mg/l
 Exposure time: 48 h

NOEC (Daphnia magna (Water flea)): 10 mg/l

LUCENTIS(R) Vials (0.3 mg/0.05 ml)Version
0.0Revision Date:
02-13-2020Date of last issue: 01-30-2020
Date of first issue: 06-10-2017

Exposure time: 48 h

Toxicity to microorganisms : EC50 (Bacteria): 146 - 774 mg/l
Exposure time: 0.08 h**Persistence and degradability****Components:****Ranibizumab:**

Biodegradability : Result: Globular proteins are generally well biodegradable

Trehalose (D+)-, 2H2O:Biodegradability : Concentration: 45.4 mg/l
Biodegradation: 85 %
Exposure time: 14 d
Method: OECD Test Guideline 301F
GLP: yes**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**Biodegradability : Result: Biodegradable
Biodegradation: 97.2 %
Testing period: 5 d

Biodegradation: 60.3 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
GLP: yes**Bioaccumulative potential****Components:****Ranibizumab:**Partition coefficient: n-
octanol/water : Remarks: No data available**Trehalose (D+)-, 2H2O:**Partition coefficient: n-
octanol/water : Remarks: No data available**L-Histidine monohydrochloride monohydrate:**Partition coefficient: n-
octanol/water : Remarks: No data available

Remarks: No data available

L-Histidine:Partition coefficient: n-
octanol/water : Remarks: Not applicable

LUCENTIS(R) Vials (0.3 mg/0.05 ml)Version
0.0Revision Date:
02-13-2020Date of last issue: 01-30-2020
Date of first issue: 06-10-2017**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**

Partition coefficient: n-octanol/water : Remarks: No data available

Water:

Partition coefficient: n-octanol/water : Remarks: No data available

Mobility in soil

No data available

Other adverse effects**Product:**Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).**Components:****Ranibizumab:**

Additional ecological information : Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

L-Histidine monohydrochloride monohydrate:

Results of PBT and vPvB assessment : This substance is not considered to be persistent, bioaccumulating and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulating (vPvB).

L-Histidine:

Additional ecological information : No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
Do not re-use empty containers.

LUCENTIS(R) Vials (0.3 mg/0.05 ml)

Version 0.0 Revision Date: 02-13-2020 Date of last issue: 01-30-2020
 Date of first issue: 06-10-2017

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation

49 CFR

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

Components	CAS-No.	Component TPQ (lbs)
------------	---------	---------------------

SARA 311/312 Hazards : No SARA Hazards

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

LUCENTIS(R) Vials (0.3 mg/0.05 ml)

Version
0.0

Revision Date:
02-13-2020

Date of last issue: 01-30-2020
Date of first issue: 06-10-2017

US State Regulations

Massachusetts Right To Know

Pennsylvania Right To Know

Water	7732-18-5
Trehalose (D+)-, 2H2O	6138-23-4

Maine Chemicals of High Concern

Vermont Chemicals of High Concern

Washington Chemicals of High Concern

The ingredients of this product are reported in the following inventories:

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Ranibizumab

L-Histidine monohydrochloride monohydrate

AICS : Not in compliance with the inventory

NZIoC : On the inventory, or in compliance with the inventory

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

KECI : Not in compliance with the inventory

PICCS : Not in compliance with the inventory

IECSC : Not in compliance with the inventory

TCSI : Not in compliance with the inventory

TSCA : Substance(s) not listed on TSCA inventory

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

SAFETY DATA SHEET


LUCENTIS(R) Vials (0.3 mg/0.05 ml)

Version
0.0

Revision Date:
02-13-2020

Date of last issue: 01-30-2020
Date of first issue: 06-10-2017

NFPA:



HMIS® IV:

HEALTH	/	0
FLAMMABILITY		0
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 02-13-2020

SAFETY DATA SHEET

LUCENTIS(R) Vials (0.3 mg/0.05 ml)

Version
0.0

Revision Date:
02-13-2020

Date of last issue: 01-30-2020
Date of first issue: 06-10-2017

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 1810